[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
May 27, 2013

Balancing the Risks and Benefits of Rituximab

JAMA Intern Med. 2013;173(10):920-937. doi:10.1001/jamainternmed.2013.743

In this issue, Safa and Darrieux1 report a new and serious type of infection after rituximab therapy: cerebral toxoplasmosis. Although rituximab has helped many patients with lymphoma and autoimmune disease for more than 10 years, it has been linked to several major infectious complications.2 Reactivation of hepatitis B, cytomegalovirus disease, and the rare but fatal progressive multifocal leukoencephalopathy are the most infamous of these infections.

First Page Preview View Large
First page PDF preview
First page PDF preview